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Abstract 
The incidence of tumors with life-threatening effects has increased gradually over time; however, the mechanisms 
involved in tumor development have not been fully elucidated. Recent studies have shown that microRNA-7 (miR-
7), which is endogenous non-coding RNA molecules of approximately 23 nucleotides, plays an important role in 
the occurrence and development of tumors as a key tumor suppressor. Mechanistic evidence showed that miR-7 is 
closely related to the growth, metastasis, and prognosis of various malignant tumors through regulating different 
target molecules, which suggest that miR-7 may be a new target for the clinical diagnosis and treatment of various 
tumors. In this review, we summarize current knowledge of the relationship between miR-7 and tumor development, 
diagnosis, and treatment.
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Background
MicroRNAs (miRNAs) are small noncoding RNAs that 
posttranscriptionally regulating target gene expression 
through base pairing to partially complementary sites 
to prevent protein accumulation by repressing transla-
tion or by inducing mRNA degradation [1, 2]. The pri-
mary transcripts of miRNA (pri-miRNA) are cleaved 
into precursor miRNA (pre-miRNA) by nuclear RNase 
III Drosha, and further processed to mature miR-
NAs by cytoplasmic RNase III Dicer [3, 4]. Up to data, 
the involvement of miRNAs in human cancer has led 
to extensive research [5–7]. More and more evidences 
showed that miRNAs were not only dysregulated in 
almost all types of cancers but also were potential spe-
cific signatures for the characterization of poorly differ-
entiated tumors, which might harbor relevant clinical 
implications. Further studies suggested that miRNAs in 
cancers could be divided into two types including onco-
genic miRNAs (Oncomirs) and tumor suppressor miR-
NAs. Oncomirs are reported upregulated in cancer cells 
and contributed to carcinogenesis by inhibiting tumor 
suppressor genes. Conversely, tumor suppressor miR-
NAs are documented could prevent cancer development 
by inhibiting the expression of oncogenes. Experimental 
data in some animal tumor models showed that silenc-
ing oncomirs with miRNA inhibitors or replacing tumor 
suppressor miRNAs with synthetic miRNA mimics may 
be valuable strategy for the treatment of solid and hema-
tological malignancies, which suggesting a particularly 
promising in translational therapy against tumors.
MicroRNA-7 (miR-7) was first identified by Lagos-
Quintana in 2001 [8]. In humans, miR-7 is encoded by 
three different genomic loci 9q21, 15q26, 19q13 respec-
tively. The products of three different DNA sequences 
(termed as pri-miR-7-1, pri-miR-7-2, and pri-miR-7-3) 
can be processed into the same mature miR-7 sequence 
which comprising 23 nucleotides [9]. The mature miR-7 
is then incorporated into a RNA-induced silencing com-
plex (RISC), which recognizes target mRNAs through 
imperfect base pairing with the miRNA and most com-
monly results in translational inhibition or destabilization 
of the target mRNA (Fig. 1). Many studies have reported 
that miR-7 is enriched in a variety of normal tissues and 
involved in both the development of multiple organs and 
biological functions of cells [10, 11]. Moreover, some 
tissues related factors could regulate the expression of 
miR-7; for example, transcription factor NeuroD/Beta2 
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Fig. 1 Structure of the human miR-7 hairpin precursors and mature sequences. MiR-7 is transcribed from three different genomic loci on chro-
mosomes 9, 15, 19 into primary miR-7 transcripts (pri-miR-7-1, pre-miR-7-2, pri-miR-7-3 respectively), which are processed into hairpin precursor 
molecules (pre-miR-7-1, pre-miR-7-2, pre-miR-7-3), and then further into the same mature miR-7 sequences, which are incorporated into the RISC 
complex and guided to miR-7 target mRNAs to repress their expression
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can bind to the promoter region of miR-7 and succes-
sively regulate its expression [12]. And Human antigen R 
(HuR) could mediate the binding of Musashi homolog 2 
(MSI2) to the conserved terminal loop of pri-miR-7, then 
modify miR-7 processing in normal cells [13]. Recent 
evidence showed that miR-7 plays an important role in 
growth, migration, and invasion of multiple cancers [14–
17]; hence, it may be a new promising target for cancer 
therapies.
MiR‑7 and breast cancer
E-cadherin and Vimentin were reported played cru-
cial roles in epithelial-mesenchymal transition (EMT) 
process, including monolayer scattering, independent 
growth, migration, and invasion, of breast cancer cells, 
which closely related to metastasis of cancer cells [18]. A 
study of breast cancer tissue specimens revealed a posi-
tive correlation between the expression levels of miR-7 
and E-cadherin, and a negative correlation between the 
expression levels of miR-7 and Vimentin [19], indicating 
miR-7 might be involved in the metastasis of breast can-
cer. Importantly, the expression level of miR-7 in meta-
static breast cancer tissues was significantly lower than 
that in normal breast tissues. Furthermore, an increase in 
the expression level of miR-7 could dramatically inhibit 
the growth and invasiveness of breast cancer cells in ani-
mal models, indicating that miR-7 plays an important 
role in metastasis of breast cancer [19].
Successive studies have demonstrated that miR-7 
can negatively regulate a variety of molecules involved 
in breast cancer cell growth, metastasis, and invasion. 
P21-activated kinase 1 (PAK1) is expressed at high lev-
els in many human cancer tissues and is closely related 
to mitosis of tumor cells, regeneration of the cytoskel-
eton structure, cell migration and apoptosis [20]. Reddy 
et al. showed that miR-7 binds to a complementary site in 
the 3′ untranslated region (UTR) of the PAK1 mRNA to 
inhibit its expression and downregulate the kinase activ-
ity of the protein, resulting in the inhibition of breast can-
cer growth [21]. In addition, Webster et al. reported that 
miR-7 inhibits epidermal growth factor receptor (EGFR) 
expression and the protein kinase B signal transmission 
pathway, thereby regulating the growth and metastasis of 
breast cancer cells [22]. MiR-7 can also inhibit the inva-
sion and metastasis of breast cancer cells by negatively 
regulating focal adhesion kinase (FAK), an important 
signaling factor that controls cell proliferation and loco-
motor activity [19]. In line with these data, the expression 
level of FAK is increased in metastatic tumors with poor 
prognosis [23]. In additions, miR-7 also can inhibit brain 
metastasis of breast cancer and the self-renewal capacity 
of breast cancer stem-like cells by regulating the expres-
sion of Krüppel-like factor4 (KLF4) [24].
The underlying mechanism through which miR-7 regu-
lates breast cancer cell growth and metastasis is complex, 
it dose not involve only the above mentioned molecular 
targets and signal transmission pathways but also some 
transcription factors and DNA damage repair processes. 
For example, Li et al. demonstrated that miR-7 can reac-
tivate the Ras association domain family 1A (Raf1A) 
and tumor suppressors claudin-6 by targeting the gene 
encoding homeobox B3 (HoxB3), therefore inhibit the 
growth and colony formation capacity of breast cancer 
cells [25]. In addition, Yu et al. showed that miR-7 binds 
to the 3′UTR of the mRNA encoding SET domain-con-
taining (lysine methyltransferase) 8 (SET8) to downreg-
ulate its expression in breast cancer cells [26]. In higher 
eukaryotes, SET8 is involved in gene transcription and 
the cell cycle progression of breast cancer cells, and is 
also related to a variety of biological processes, includ-
ing DNA damage and repair [27]. Moreover, MiR-7 can 
reduce the monomethylation of histone H4 lysine 20 by 
targeting SET8, then inhibiting the occurrence, devel-
opment, and invasion of breast cancer [26]. In addition, 
some studies reported that miR-7 accelerates spontane-
ous DNA damage and sensitizes breast cancer cells to 
this type of damage. Taken together, these findings indi-
cate that miR-7 can regulate the development and pro-
gression of breast cancer through multiple targets or 
pathways; hence, miR-7 based breast cancer gene ther-
apy is expected to become an important area of related 
research.
The current understanding of the mechanism of regu-
lating miR-7 expression in breast cancer cells still is lim-
ited. MiR-7 expression is upregulated by the transcription 
factor HoxD10. When the level of HoxD10 is decreased, 
the expression level of miR-7 is also decreased. Succes-
sively, the expression level of its target molecule PAK1 
is increased significantly, the growth and invasiveness of 
breast cancer cells is enhanced [21]. Due to the complex-
ity of the mechanisms of regulation of miRNAs, addi-
tional analyses on off factors that affect miR-7 expression 
in breast cancer are required.
MiR‑7 and lung cancer
MiR-7 plays an important role in suppressing the migra-
tion, colony formation, and cell-cycle progression of lung 
cancer cells. Reducing the amount of miR-7 can promote 
the growth and metastasis of human lung carcinoma 
A549 and H1299 cells significantly [28]. Furthermore, 
increasing the level of miR-7 can reduce the levels of 
cell-cycle-associated proteins and inhibit the prolifera-
tion of human lung cancer cells, suggesting that miR-7 is 
closely related to development of lung cancer. It is well 
known that epidermal growth factor receptor (EGFR) is 
critical factor for the growth and metastasis of human 
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lung cancer cells [29, 30]. Mechanistic evidence showed 
that miR-7 can inhibit the proliferation of lung cancer 
cells through regulating the expression of EGFR by bind-
ing to the 3′UTR region of EGFR mRNA [28]. In addi-
tion, Xiong et al. showed that miR-7 downregulated the 
expression of the gene encoding BCL-2, thereby inhib-
iting the proliferation and promoting the apoptosis of 
lung adenocarcinoma A549 cells [31]. Other studies also 
reported that miR-7 targets and downregulates protea-
some activator 28 subunit γ, which contributes to the 
carcinogenesis of non-small cell lung cancer, and inhib-
its apoptosis and accelerates the cell cycle in lung cancer 
cells [32]. Moreover, Zhou et al. showed that the regula-
tory effect of miR-7 on the growth of human lung cancer 
cells may be associated with the downregulated expres-
sion of Solute Carrier Family 7 (Amino Acid Transporter 
Light Chain, L System), Member 5 (SLC7A5), which was 
a member of the l-type amino acid transporter (LAT) 
family and was involved in the growth of cancer cells 
[33–35]. In contrast to these literatures, other studies 
showed that inhibition of miR-7 could reduce the growth 
of lung cancer cell line A549 cells [36]. Based on these 
contradictory data, we propose that this might reflect 
the fact that miR-7 plays a crucial role in lung cancer cell 
growth, invasion, and metastasis, although the mecha-
nisms involved in regulating these processes may be 
complex, which was closely related to the cellular con-
text, growth conditions and specific targeted genes.
A number of studies have shown that miR-7 also is 
involved in the signal transduction and regulatory pro-
cesses of other membrane-bound proteins in lung cancer 
cells, such as the pattern-recognition molecules Toll-like 
receptor 9 (TLR9). Our recent study showed that miR-7 
may negatively regulate the phosphoinositide 3-kinase 
(PI3K)/AKT signaling pathway by acting on PI3Kregula-
tory subunit 3, thereby blocking the TLR9 signal trans-
duction process and inhibiting cancer cell growth and 
metastasis [37]. Furthermore, activation of TLR9 sign-
aling can inhibit the cleavage of the endogenous miR-7 
precursor in lung cancer cells by inducing the expression 
of human antigen R (HuR), therefore reduce the level of 
mature miR-7 and accelerate the growth and metastatic 
progression of the cells [38].
The treatment of lung cancer could lead to an acquired 
resistance to EGFR tyrosine kinase inhibitors (TKIs). 
However, in about 50 % of patients with TKIs resistance, 
this resistance is caused by a T790M mutation in exon 
20 of the EGFR gene [39]. Interestingly, Rai et al. showed 
that expression of exogenous miR-7 in nude mice bearing 
RPC-9 and H1975 lung cancer cells, which have a high 
tolerance to TKIs, inhibited the growth of tumors, sug-
gesting that miR-7, as a tumor suppressor miRNA, may 
be an important target for lung cancer gene therapy [40].
MiR‑7 and brain cancer
MiR-7 is enriched in the brain and regulates neuronal 
differentiation, maturation, and survival [41].There is 
increasing evidence that miR-7 is a robust suppressor of 
the growth, metastasis, and invasion of glioblastoma; for 
example, Liu et al. showed that miR-7 can suppress glio-
blastomagenesis by regulating the PI3K/AKT and Raf/
mitogen-activated protein kinase/extracellular signal-
regulated kinase (ERK) pathways, which are downstream 
signaling pathways of the EGFR [42]. Furthermore, miR-7 
may regulate brain tumorigenesis by targeting oncogenic 
proteins and critical factors such as c-KIT, Y box binding 
protein 1, AKT2, cell division control protein 42, cyclin-
dependent kinase 6, and transforming growth factor β2 
(TGF-β2), which can also affect the expression of miR-7 
in a feedback loop [43]. Similar to the anti-angiogenic 
drug sunitinib, miR-7 can reduce vascularization in the 
chick chorioallantoic membrane assay. Furthermore, 
local application of miR-7 to neuroblastoma model mice 
harboring human glioblastoma xenografts reduces angi-
ogenesis and tumor cell proliferation by targeting the 
3′UTR of the FAK mRNA [44]. In addition, miR-7 also 
can inhibit glioblastoma cell invasion by downregulat-
ing the expression levels of p-ERK1/2, p-AKT, Raf-1, 
and cyclin D1 [42]. There also are some reports suggest-
ing that brain-enriched ciRS-7, a circular RNA contain-
ing 70 conserved miR-7 target sites, can downregulate 
the expression of miR-7 and promote the development 
of neuroblastomas and astrocytomas [45]. Conversely, 
miR-671 can release the expression of miR-7 by binding 
to ciRS-7 [46]. Overall, these findings suggest that miR-7 
may be a potential therapeutic target to suppress brain 
tumorigenesis, metastasis, and invasion.
MiR‑7 and other tumors
Recently, a large number of studies have demonstrated 
that miR-7 is related to liver cancer [47], colorectal can-
cer [48], gastric tumor [49], and ovarian cancer [50]. 
Using immunohistochemistry, real-time PCR, and lucif-
erase reporter genes  assay, Needhamsen et  al. showed 
that the human gene encoding paired box 6 (PAX6) is 
an putative target of miR-7 [51]. PAX6 is a highly con-
served transcription factor that is expressed in colorec-
tal cancer cells and plays an important regulatory role in 
the development of colorectal cancer [52]. Overexpres-
sion of PAX6 in human colonic adenocarcinoma SW480 
cells activates the ERK/PI3K signaling pathway and 
upregulates the expression levels of MMP2 and MMP9, 
resulting in the enhancement of cancer cell growth, pro-
liferation, and metastatic capacity. By contrast, miR-7 
reduces PAX6 expression in colorectal cancer cell lines 
and inhibits the corresponding signaling through the 
ERK/PI3K pathway, resulting in downregulated growth, 
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proliferation, and metastasis of these cells significantly 
[53]. Meanwhile, in vivo experiments revealed that miR-7 
could bind to the 3′ UTR of the mRNA encoding Yin 
Yang 1, which was a multifunctional transcription factor 
and was reported contributed to growth of cancer cells, 
and inhibit its expression, thereby attenuated colorectal 
cancer cell growth and invasion [54].
Fang et  al. showed that miR-7 arrests hepatocellular 
carcinoma cells in the G0/G1 phase and negatively regu-
lates the PI3K/AKT pathway by targeting AKT, mam-
malian target of rapamycin, and ribosomal protein S6 
kinase, which are key signaling molecules involved in the 
promotion of liver cancer cell growth and metastasis [55]. 
MiR-7 may also play an important role in discriminating 
between benign and malignant cells in B-chronic lym-
phocytic leukemia [56]. In addition, Zhao et  al. showed 
that miR-7 binds to the 3′ UTR of the mRNA encoding 
insulin-like growth factor 1 receptor and induces cad-
herin expression and reversal of the epithelial-mesen-
chymal transition of gastric cancer cells, successively 
inhibited gastric cancer metastasis [57]. A number of 
other types of cancer are also reported closely related 
to miR-7 (summarized in Table  1), suggesting that this 
miRNA may be a novel clinical target for the treatment of 
a variety of tumors.
MiR‑7 and tumor diagnosis, therapy
Multiple studies have suggested that miR-7 can be used 
as a potential diagnostic marker of cancer. For example, 
the expression level of miR-7 is significantly lower in lung 
cancer tissues than normal lung tissues, and downregula-
tion of miR-7 expression is associated with lung cancer 
metastasis [32]. Kitano et al. showed that miR-7 expres-
sion level predicts thyroid cancer prognosis with an 
accuracy of approximately 76 % [69]. Other groups used 
non-invasive detection methods and found that the 
serum level of miR-7 is significantly lower in patients 
with colorectal cancer than healthy controls [70]. Moreo-
ver, fecal expression levels of miR-7 was remarkable dif-
ference between colorectal cancer patients and healthy 
controls, suggesting that non-invasive detection of miR-7 
can be used for the auxiliary diagnosis of colorectal can-
cer [71]. In addition, other studies have suggested that 
miR-7 may be an important clinical predictor of recur-
rence. For example, Duncavage et  al. showed that the 
expression level of miR-7 in relapsed lung cancer patients 
is significantly lower than that in healthy individuals, 
suggesting a relationship between reduced expression of 
miR-7 and lung cancer recurrence [72].
To the therapy against cancer, the related progres-
sion still is limited but promising. Overexpression of 
Table 1 The targets of miR‑7 in different tumor types
FAK focal adhesion kinase, PAK1 p21 activated kinase 1, EGFR epidermal growth factor receptor, KLF4 Krüppel like factor 4, HoxB3 homeobox B3, SET8 SET domain-
containing (lysine methyltransferase) 8, PA28γ proteasome activator 28 subunit γ, HuR human antigen R, PI3KCD phosphoinositide 3-kinase catalytic subunit delta, 
mTOR mammalian target of rapamycin, p70S6 K ribosomal protein S6 kinase, GSK-3β glycogen synthase kinase 3, ciRS-7 circular RNA sponge for miR-7, XRCC2 
X-ray repair complementing defective repair in Chinese hamster cells 2, PAX6 paired box 6, YY1 Yin Yang 1, IGF1R insulin-like growth factor 1 receptor, TET2 tet 
methylcytosine dioxygenase 2, FGFR3 fibroblast growth factor receptor 3, XIAP X-linked inhibitor of apoptosis protein, IRS-2 insulin receptor substrate 2, RECK 
reversion-inducing cysteine-rich protein with Kazal motifs, 4-HPR N-(4-hydroxyphenyl) retinamide, EGCG (-)-epigallocatechin-3-gallate, MAPK mitogen-activated 
protein kinase, ACK1 associated cdc42 kinase 1
Tumor type Target site(s) Reference(s) Role of target site
Breast cancer FAK, PAK1, EGFR, KLF4, HoxB3, SET8 [19, 21, 22, 24–26] Suppressor
Lung cancer PA28γ, BCL-2, EGFR, SLC7A5, HuR [32, 35, 38 39] Suppressor
Hepatocellular carcinoma CCNE1, PI3KCD, mTOR, p70S6 K, GSK-3B [48, 54] Suppressor
Glioma EGFR, C-KIT, FAK, ERK, ciRS-7 [42–44, 46] Suppressor
Colorectal cancer XRCC2, PAX6, YY1 [49, 52, 53] Suppressor
Gastric cancer EGFR, IGF1R [42, 56] Suppressor
Acute myelocytic leukemia TET2 [58] Suppressor
Urothelium carcinoma FGFR3 [59] Suppressor
Cervical cancer XIAP [60] Suppressor
Renal carcinoma None reported [61] Oncogene
Melanoma IRS-2 [62] Suppressor
Ovarian cancer EGFR, ERK [50] Suppressor
Oral cancer RECK [63] Oncogene
Neuroblastoma 4-HPR, EGCG [64] Suppressor
Pancreatic carcinoma MAPK [65] suppressor
Pleural mesothelioma None reported [66] Suppressor
Schwannoma tumors EGFR, ACK1, PAK1 [67] Suppressor
Tongue squamous carcinoma IGF1R [68] Suppressor
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miR-7 using a eukaryotic expression vector can inhibit 
the growth of TKI-resistant lung cancer cell significantly 
in vivo. Tazawa et al. constructed an oncolytic adenovirus 
that upregulated miR-7 expression and induced apopto-
sis of human tumor cells through the activation of the 
transcription factor E2F1/miR-7/EGFR pathway, suggest-
ing a potential new method of inducing tumor cell death 
by controlling miR-7 levels [73]. In addition, Lee et  al. 
reported that overexpression of miR-7 increases the radi-
osensitivity of cancer cells, suggesting that this miRNA 
may have a positive effect on radiation therapy of tumors 
[74]; however, further analyses are required to clarify the 
relationship between tumor diagnosis/treatment and the 
expression levels of miR-7 in different tissues and organs. 
In all, the development of miR-7-based therapeutic strat-
egy, including the application of efficient synthetic sys-
tems for miR-7 delivery, remains to be fully investigated 
in future.
Conclusion
In this review, we have tried to discuss miR-7 as a 
promising target in cancers. Although substantial 
progress has been made in the mechanisms by which 
miR-7 controls tumor cell growth, proliferation, inva-
sion, and metastasis, however, a number of issues 
require further investigation, such as the precise 
regulatory mechanisms of miR-7, the relationships 
between its target genes, and the ways in which tar-
geting miR-7 can be used to develop agents that have 
desirable effects on distinct type of cancers, which will 
provide robust and valuable information related to the 
clinical diagnosis, treatment, and prognoses of various 
cancers.
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